{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:11:29Z","timestamp":1791389489351,"version":"4.3.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10875-024-01852-0","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T17:19:34Z","timestamp":1735838374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Baricitinib-Induced Remission of Alopecia Universalis in a Child with NFKB2-Associated Immune Dysregulation"],"prefix":"10.1007","volume":"45","author":[{"given":"C.","family":"Blokhuis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.R.","family":"Leahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.D.","family":"Irvine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Browne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Flinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"issue":"3","key":"1852_CR1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s12016-021-08883-0","volume":"61","author":"C Zhou","year":"2021","unstructured":"Zhou C, et al. Alopecia Areata: an update on etiopathogenesis, diagnosis, and management. Clin Rev Allergy Immunol. 2021;61(3):403\u201323.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"1852_CR2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000530432","volume":"9","author":"H Englander","year":"2023","unstructured":"Englander H, Paiewonsky B, Castelo-Soccio L. Alopecia Areata: a review of the genetic variants and Immunodeficiency Disorders Associated with Alopecia Areata. Skin Appendage Disord. 2023;9(5):325\u201332.","journal-title":"Skin Appendage Disord"},{"key":"1852_CR3","doi-asserted-by":"publisher","first-page":"1243556","DOI":"10.3389\/fimmu.2023.1243556","volume":"14","author":"T Passeron","year":"2023","unstructured":"Passeron T, et al. Inhibition of T-cell activity in Alopecia Areata: recent developments and new directions. Front Immunol. 2023;14:1243556.","journal-title":"Front Immunol"},{"key":"1852_CR4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3389\/fimmu.2019.00297","volume":"10","author":"C Klemann","year":"2019","unstructured":"Klemann C, et al. Clinical and immunological phenotype of patients with primary Immunodeficiency due to damaging mutations in NFKB2. Front Immunol. 2019;10:297.","journal-title":"Front Immunol"},{"issue":"1","key":"1852_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/cr.2010.177","volume":"21","author":"SC Sun","year":"2011","unstructured":"Sun SC. Non-canonical NF-\u03baB signaling pathway. Cell Res. 2011;21(1):71\u201385.","journal-title":"Cell Res"},{"key":"1852_CR6","unstructured":"Meissner J et al. Type-specific impacts of protein defects in pathogenic NFKB2 variants: Novel Clinical findings from 138 patients. J Allergy Clin Immunol Pract 2024 22:S2213-2198(24)01070-5."},{"issue":"7988","key":"1852_CR7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41586-023-06717-x","volume":"623","author":"T Le Voyer","year":"2023","unstructured":"Le Voyer T, et al. Autoantibodies against type I IFNs in humans with alternative NF-\u03baB pathway deficiency. Nature. 2023;623(7988):803\u201313.","journal-title":"Nature"},{"issue":"2","key":"1852_CR8","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.jaci.2014.12.1867","volume":"135","author":"E Higgins","year":"2015","unstructured":"Higgins E, et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol. 2015;135(2):551\u20133.","journal-title":"J Allergy Clin Immunol"},{"issue":"20","key":"1852_CR9","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1056\/NEJMe2403419","volume":"390","author":"MA Su","year":"2024","unstructured":"Su MA. JAK inhibition immunotherapy for APS-1. N Engl J Med. 2024;390(20):1918\u201321.","journal-title":"N Engl J Med"},{"key":"1852_CR10","doi-asserted-by":"publisher","first-page":"1152513","DOI":"10.3389\/fimmu.2023.1152513","volume":"14","author":"D Wei","year":"2023","unstructured":"Wei D, et al. Efficacy and safety of different JAK inhibitors in the treatment of Alopecia Areata: a network meta-analysis. Front Immunol. 2023;14:1152513.","journal-title":"Front Immunol"},{"issue":"3","key":"1852_CR11","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s40272-024-00620-2","volume":"26","author":"LL Westerkam","year":"2024","unstructured":"Westerkam LL, et al. Treatment options for Alopecia Areata in Children and adolescents. Paediatr Drugs. 2024;26(3):245\u201357.","journal-title":"Paediatr Drugs"},{"issue":"3","key":"1852_CR12","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/jdv.19665","volume":"38","author":"M Senna","year":"2024","unstructured":"Senna M, et al. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2. J Eur Acad Dermatol Venereol. 2024;38(3):583\u201393.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1852_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jaci.2023.10.018","volume":"153","author":"M Fischer","year":"2024","unstructured":"Fischer M, et al. JAK inhibitor treatment for inborn errors of JAK\/STAT signaling: an ESID\/EBMT-IEWP retrospective study. J Allergy Clin Immunol. 2024;153(1):275\u2013e28618.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1852_CR14","doi-asserted-by":"publisher","first-page":"ofx202","DOI":"10.1093\/ofid\/ofx202","volume":"4","author":"O Zimmerman","year":"2017","unstructured":"Zimmerman O, et al. Risks of Ruxolitinib in STAT1 gain-of-function-Associated severe fungal disease. Open Forum Infect Dis. 2017;4(4):ofx202.","journal-title":"Open Forum Infect Dis"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-024-01852-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-024-01852-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-024-01852-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T15:46:53Z","timestamp":1777304813000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-024-01852-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1852"],"URL":"https:\/\/doi.org\/10.1007\/s10875-024-01852-0","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"3 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"62"}}